Understanding the root cause for poor exposure driven by the key barriers to absorption for a given compound can drastically reduce the time and effort spent on selecting and progressing multiple technologies.
TORONTO (PRWEB) April 14, 2021
Evaluating formulation approaches for increasing oral bioavailability are becoming routine early on in formulation development programs. Selecting the appropriate technology for your compound requires careful consideration of the compound physicochemical properties, target dose and pharmacokinetic profile, as well as overall market image. Understanding the root cause for poor exposure driven by the key barriers to absorption for a given compound can drastically reduce the time and effort spent on selecting and progressing multiple technologies.
Register for this webinar to learn about a general overview of some of the most common bioavailability-enhancing technologies for poorly soluble compounds and a strategic framework for identifying and selecting the appropriate technology. A case study demonstrating the approach will be presented for a poorly soluble BCS Class II compound.
For more information, or to register for this event, visit Achieving Bioavailability Enhancement for Poorly Soluble Compounds.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.